Skip to main content
OpenTrials

Clinical trial condition

Urinary Bladder Neoplasms

Explore clinical trials studying Urinary Bladder Neoplasms. Study availability and eligibility vary by location and protocol.

98 public trials 41 recruiting studies
Refine in advanced search Browse all conditions

Urinary Bladder Neoplasms trial results

Completed

Intravesical Adjuvant Electromotive Mitomycin-C

NCT01920269

Conditions
Bladder Cancer TNM Staging Primary Tumor (T) T1, Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer Transitional Cell Grade, +15 more
Locations
  • Tor Vergata University, Department of experimental Medicine and Surgery/Urology Rome, RM, Italy
View Trial Details
Completed

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer

NCT00782587

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • BCG Oncology, PC Phoenix, Arizona, United States
  • Advanced Urology Medical Center Anaheim, California, United States
  • Medresearch La Mesa, California, United States
  • Malcolm Randall Veterans Administration Gainesville, Florida, United States
View Trial Details
Completed

A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer

NCT00192049

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician Beersheba, Israel
  • For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician Haifa, Israel
  • For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician Jerusalem, Israel
  • For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician Kfar Saba, Israel
View Trial Details
Completed

Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.

NCT00191711

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your physician Sesto Fiorentino, Florence, Italy
View Trial Details
Active, Not Recruiting

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 229 locations
View Trial Details
Active, Not Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +15 more
Locations
  • Urology Centers Alabama Homewood, Alabama, United States
  • BCG Oncology Phoenix, Arizona, United States
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • Arizona Institute of Urology Tucson, Arizona, United States
View all 86 locations
View Trial Details
Active, Not Recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • Research Site Auchenflower, Australia
  • Research Site Box Hill, Australia
  • Research Site Brisbane, Australia
  • Research Site Kogarah, Australia
View all 120 locations
View Trial Details
Active, Not Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Arkansas Urology Little Rock, Arkansas, United States
  • Genesis Research LLC 1 Los Alamitos, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
View all 123 locations
View Trial Details

Related conditions